Alzamend Neuro Inc (ALZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has a cash flow conversion efficiency ratio of -3.815x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.80 Million) by net assets ($733.21K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alzamend Neuro Inc market cap and net worth for the company's overall valuation and market capitalisation.
Alzamend Neuro Inc - Cash Flow Conversion Efficiency Trend (2016–2026)
This chart illustrates how Alzamend Neuro Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alzamend Neuro Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alzamend Neuro Inc ranked by their cash flow conversion efficiency. See ALZN cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Syra Health Corp. Class A Common Stock
NASDAQ:SYRA
|
0.576x |
|
Ragnar Metals Ltd
AU:RAG
|
-0.028x |
|
Luminar Technologies
NASDAQ:LAZR
|
0.159x |
|
Rochester Resources Ltd
V:RCT
|
-0.031x |
|
Asia Fiber Public Company Limited
BK:AFC
|
0.050x |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
-0.396x |
|
Bhakti Agung Propertindo
JK:BAPI
|
-0.002x |
|
Pipe Works L. Girakian Profil S.A.
AT:PROFK
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Alzamend Neuro Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of Alzamend Neuro Inc from 2016 to 2026. View latest Alzamend Neuro Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | $733.21K | $-8.07 Million | -11.003x | -564.78% |
| 2025-04-30 | $3.97 Million | $-6.57 Million | -1.655x | -151.92% |
| 2024-04-30 | $-2.59 Million | $-8.27 Million | 3.188x | +208.80% |
| 2023-04-30 | $3.05 Million | $-8.92 Million | -2.930x | -491.46% |
| 2022-04-30 | $13.35 Million | $-6.61 Million | -0.495x | +63.23% |
| 2021-04-30 | $2.01 Million | $-2.71 Million | -1.347x | +52.81% |
| 2020-04-30 | $821.71K | $-2.35 Million | -2.855x | +13.44% |
| 2019-04-30 | $316.92K | $-1.05 Million | -3.298x | -272.82% |
| 2018-04-30 | $2.32 Million | $-2.05 Million | -0.885x | -136.52% |
| 2017-04-30 | $-584.93K | $-1.42 Million | 2.422x | -98.61% |
| 2016-04-30 | $-106.00 | $-18.49K | 174.453x | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more